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Combinatorial gene inactivation using an RNAi library is a powerful approach to discovering novel functional genes. However, generation of a
comprehensive RNAi library remains technically challenging. In this report, we describe a simple and novel approach to designing gene-family-
specific RNAi libraries by targeting conserved motifs using degenerate oligonucleotides. We created an siRNA library in the pHUMU vector using
partially randomized sequences targeting the consensus region in the ZnF_C4 signature motif of the nuclear hormone receptors and thus against
the entire receptor superfamily. For proof of principle, we adapted a reporter assay to screen this library for receptors that might be involved in
reducing amyloid β peptide accumulation. We modified a previously described luciferase reporter assay to measure the amyloid β precursor
cleavages occurring only between β- and γ-secretase cleavage sites, thus excluding the major γ-secretase activities that could generate neurotoxic
Aβ peptides. Our screen using this assay identified siRNA vectors that specifically increase the Aβ40/42 cleavage and pointed to a potential
receptor target, ROR-γ. SiRNAs targeting other regions of ROR-γ not only confirmed the observed reporter activity but also reduced the level of
the toxic Aβ peptides. The results demonstrated a general principle for the creation and application of this RNAi library approach for functional
gene discovery within a predefined protein family. The discovered negative effect of ROR-γ on the degradation of the toxic Aβ peptides may also
provide a potential drug target or targetable pathway for intervention of Alzheimer disease.
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inactivation reverses disease phenotype or slows down disease
progression. RNAi efficiently inhibits gene expression and thus
mimics many drug effects. Combinatorial gene inactivation
using RNAi libraries has recently become a method of choice to
investigate gene function or identify new therapeutic targets [1–
4]. RNAi libraries can be delivered as short double-stranded
RNA in an arrayed form or in gene expression vectors in an
arrayed [4] or pooled format [5–7]. In the first case, siRNAs
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doi:10.1016/j.ygeno.2006.03.010families or pathways were chemically synthesized individually
in an arrayed form (e.g., 96-well format). This approach has
been broadly used in high-throughput discovery of functional
genes, and many such libraries have become available from
commercial sources. The major limitation of this approach is the
high cost of the repeated synthesis of a consumable complex
library. Also, synthetic siRNA is not suitable for cotransfection
experiments with reporter DNA plasmids. In the second case,
RNAi library vectors are constructed either by PCR [4] or by
cloning (plasmid vectors and viral vectors) [1,2,8]. These are
renewable and suitable for cotransfection with other vectors
(e.g., reporters) [3,9]. However, technical challenges still
remain for the creation of such libraries, thus limiting their
application. We recently described a special RNAi vector based
on a dual opposing promoter siRNA expression cassette
283J.-P. Yang et al. / Genomics 88 (2006) 282–292(pMUHU) that can be used to construct an siRNAvector readily
by a “single-parallel cloning process,” facilitating high-
throughput screening using a reporter cotransfection [3].
There are several methods of designing RNAi vector
libraries with regard to their targets. The first approach is to
construct individual siRNAs against defined sequences of each
target (usually up to four siRNA per gene), a labor-intensive
process if a large number of gene targets are involved. The
second potential approach is to generate a combinatorial library
by randomizing the entire siRNA sequences, thus covering
every possible gene, similar to the randomized ribozyme
libraries described previously [10–12]. However, the fully
randomized siRNA library, with 21 nucleotides in length, would
have a complexity of 2.2 × 1012, far exceeding the complexity
of the mammalian genome, and would not be practical to use.
The third approach is to clone short double-stranded cDNA
sequences of 21–27 bp directly into expression vectors. There
are reports of successful examples using this strategy [5–7], but
the efficiency of construction and the representativeness of
these libraries are still not optimal.
We are interested in studying specific gene families,
particularly those considered druggable. We devised an
extremely simple and cost-effective method for expressing a
library of siRNAs targeting all the genes encoding a
predetermined protein family. Many protein families are
characterized by one or more signature motifs of a highly
conserved domain(s) critical for the biochemical functions of
the family, e.g., the kinase domain for kinases. Our method is
based on the design of semirandomized, degenerate oligonu-
cleotides that target the conserved domains of the gene
family.
Nuclear hormone receptors (NHRs) are transcription
factors with certain structural and functional characteristics
[13,14]. The family of NHRs contains 45 known members
and possibly additional unknown members. All members
contain two conserved signature motifs: the zinc finger_C4
domain (ZnF_C4 or C4 zinc finger) and the HOLI (hormone
ligand) motif. These two domains coordinate with each other
and thus are responsible for switching on/off or up/down-
regulating the expression of the targeted genes. The ZnF_C4
motif is located inside the DNA binding domain of NHRs and
determines the DNA-binding specificity for a given NHR,
while the HOLI motif is located within the ligand binding
domain of NHRs and determines the ligand specificity of a
given NHR. In this proof-of-principle study, we designed and
constructed an siRNA library against human NHRs using the
degenerate sequences derived from the signature motif
ZnF_C4 of NHRs.
Alzheimer disease (AD) is the most prevalent neurode-
generative disease. During AD progression, protein deposits
known as “amyloid” form between neurons within senile
plaques and cerebral blood vessels. The formation of amyloid
plaques is believed to contribute to the degradation of neurons
and subsequent AD development [15]. The principal
proteinaceous component of the toxic amyloid is the amyloid
β peptides around 40 kDa in size. These Aβ species with
varying carboxyl termini, commonly known as Aβ40 andAβ42, are generated from the amyloid β precursor protein
(APP) through sequential proteolytic cleavages, mainly
through the combined actions of β- and γ-secretases. Aβ42
is considered the main neurotoxic component. Certain
enzymes have recently been implicated in the degradation
of the toxic Aβ [16]. It is widely believed that any
mechanism causing a reduction in the toxic Aβ cleavage
products, either by reducing its formation or by increasing its
degradation, would provide benefit to the treatment of AD.
We were interested in identifying gene targets whose
inactivation reduces the toxic Aβ42 fragment. A robust 96-
well format screening assay that measures the degradation of
the Aβ peptides would facilitate this effort. Although enzyme-
linked immunosorbent assays (ELISAs) to measure Aβ40 and
Aβ42 levels directly and specifically are commercially
available, they are not sufficiently sensitive and reliable as a
screening tool in combination with RNAi library vector
transfection due to low and variable transfection efficiency, as
well as transfection-associated cytotoxicity. Komano et al.
recently described a novel luciferase reporter assay for APP
cleavage [17]. This assay employs a recombinant protein
containing a portion of APP fused to the mouse Notch-
intracellular domain (NICD). Cleavage of this recombinant
protein within APP domain by γ-secretase or other proteases
allows the translocation of the NICD to the nucleus, where it
activates the firefly luciferase reporter (Fig. 2A). γ-Secretase
cleaves at positions 40 and 42 to generate Aβ40 and the toxic
Aβ42. However, γ-secretase is not considered a good drug
target since it plays many vital cellular functions. For
instance, it also cleaves Notch, an essential molecule for
neurological function [16]. We are therefore interested in
activities that cleave upstream of the major γ-secretase sites
and that are responsible for the degradation of the toxic Aβ
peptides (Fig. 2B, 1).
In this study, we have developed a unique reporter assay to
measure the cleavage (or degradation) activities of the toxic Aβ
peptides and used this to screen the NHR siRNA library for
receptors whose silencing would lead to reduction of the toxic
Aβ peptides. Our screen identified ROR-γ (retinoic acid
receptor (RAR)-related orphan receptor) as a novel target.
ROR-γ had not been linked to Aβ degradation previously. This
discovery not only revealed potential new mechanisms and
therapeutic opportunities for AD, but also demonstrated the
utility of this NHR and other similarly constructed siRNA
libraries.
Results
Construction of an siRNA library targeting the human nuclear
hormone receptor family using degenerate sequences against
ZnF_C4 consensus sequences
Database searches revealed 45 unique proteins containing
both ZnF_C4 and HOLI domains, most of them being
previously described as NHRs and the few remaining being
hypothetical ones. There are also >100 known or hypothetical
proteins with only one of the two conserved motifs. The present
Table 1
Subgroups of NHRs
Variant Signature motif No. of known members
1 TCEGCKG 9
2 SCEGCKG 9
3 TCEGCKS 2
4 ACDGCSG ACNGCSG 2
5 TCDGCKG 2
SCDGCKG
6 ACEGCKG 7
7 TCESCKG 6
8 TCGSCKV 4
9 SCEACKA 4
Total 45
284 J.-P. Yang et al. / Genomics 88 (2006) 282–292study focuses only on the 45 members with both domains. We
set out to design siRNA against the relatively more conserved
ZnF_C4 domain. We aligned the 45 unique protein sequences
and identified, in the ZNF_C4 domain, three conserved motifs
of 7 or 8 amino acids with the following sequences, in which x
stands for amino acids that are not completely conserved in all
45 proteins and C stands for the cysteine amino acid that is
conserved in all 45 proteins: (1) CxxFFxRx, (2) xCxxxCxF, and
(3) xCxxC(K/S)x. These motifs are sufficiently long for a
functional siRNA (21–24 bp). The presence of the constant Phe
(F) in the first two motifs negates their usefulness, since
phenylalanine is coded by TTT or TTC, which triggers a
termination signal for the Pol III promoter. Therefore, the third
consensus sequence was chosen to design the NHR siRNA
library. Careful comparison of this motif with all 45 known
members indicates that some x residues are not totally random.
The actual consensus amino acid sequence is represented by (T/
S/A)-C-(D/E/G/N)-(G/S/A)-(C)-(K/S)-(A/G/S/V), which can be
“reverse-translated” to the nuclei acid sequences. One could
design just one degenerate oligonucleotide by fixing the
constant positions while partially randomizing the variableTable 2
Oligos of the NHR-siRNA library
The underlined letters are nucleotide symbols, while those beneath the lines are the opositions. The expression cassette with such degenerate
sequences would constitute a library with a complexity of
10,616,832. This complexity is intermediate between a
sequence-specific siRNA library and a fully randomized library.
This complexity is easily manageable if used in a pooled format
[10–12,22]. However, the majority of the members are still
superfluous.
To reduce the complexity of the library further, we
subdivided the 45 proteins into nine groups, each comprising
members having a relatively higher number of constant amino
acids than that of the entire family (see Table 1). Due to the
codon redundancy and the genetic shift in the evolutionary
course, the same amino acid sequences do not necessarily
correspond to the same nucleotide sequences. Therefore, we
aligned the nucleotide sequences encoding the motif from
individual members directly to determine the conserved and
variable positions for the nine subgroups. In this way, we
generated an siRNA library of a total complexity of 1656 (see
Table 2). This complexity, although still including many
superfluous siRNAs, is sufficiently low for efficient cloning
and downstream biological screening.
The nine degenerate oligonucleotides and the flanking
sequences were chemically synthesized (Fig. 1A) [3]. These
oligomers were pooled together according to their represen-
tation within the NHR family. The sense-strand siRNA
oligonucleotides were annealed with the two adapter oligo-
nucleotides and subsequently ligated into the pHUMU vector
to yield the pHUMU-siNR library vector with a partial single
strand at the degenerate siRNA coding sequences (N21) (Fig.
1A) [3]. The ligated vectors were transformed into bacteria,
allowing the bacteria to fill in the single-stranded gap [3,10].
The final structure of the pHUMU-siNR-Lib vector contains
an siRNA expression cassette consisting of opposing human
and murine U6 promoters driving both sense and antisense
strands of siRNA transcription, both with the initiationne-letter abbreviations for amino acids. Each underlined unit stands for a codon.
Fig. 1. (A) Structure of pHUMU-siNR-Lib vector and the resulting siRNAs. (B) The silencing of luciferase gene expression in a cotransfection assay using pHUMU-
siLuc. Various amounts of pHUMU-siLuc plasmid vector and various amounts of pHUMU-siCTL vector, with total amount of DNA constant, were cotransfected into
HeLa cells together with a constant amount of the target, the firefly luciferase expression plasmid vector. The silencing effects were measured by standard luciferase
assay.
285J.-P. Yang et al. / Genomics 88 (2006) 282–292nucleotide G (+1), and the termination sequence CTTTTT,
where C (+23) is complementary to the G (+1) of the
antisense siRNA gene and the five T’s constitute the
termination signal [3]. Transcription of the siRNA will
terminate after two T’s (Fig. 1A). This creates the 25-
nucleotide coding sequence for the siRNA library: GN21CTT
(Fig. 1A). The most salient feature of the pHUMU vector is
the simplicity in constructing such an siRNA library [3].
Sequencing of 50 clones from the constructed library showed
that they all contained distinct sequences, confirming the partial
randomness of the library surrounding the consensus sequences
(data not shown). The siRNA library cassette could then be
subcloned into a variety of vectors for different uses. To facilitate
the luciferase-based reporter assay for functional screening, we
further arrayed the pHUMU-siNR library into five 96-well plates
with each well containing 10 clones. A total of 4800 colonies
were arrayed, which is equivalent to three times the maximal
complexity of the library. The arrayed plates should thus cover
every NHR member with high probability. During transient
cotransfection, cells take up large amounts of DNAs and thus
each transfected cell should take up all 10 siRNA vectors. To
determine how much dilution of the functional plasmid DNA
was tolerable, we tested luciferase silencing by cotransfection of
HeLa cells with the firefly luciferase reporter plasmid and
different inputs of the pHUMU-siLuc vector (at 1:1 to 1:10 ratios
to pHUMU-siCTL). Our result demonstrated that the luciferase
silencing was effective even when the vectors were diluted 10-
fold (Fig. 1B), which indicates that the format of 10 different
vectors in 1 well seems adequate.Modified luciferase reporter assay for the cleavage of toxic Aβ
peptides
We set out to modify the luciferase-based APP cleavage
assay developed by Komano et al. to measure protease cleavage
upstream of major γ-secretase sites. First, we modified the
original pC53NICD construct to create pNotch-Aβ (Fig. 2B, 1)
in which the two dominant γ-secretase cleavage sites were
removed by mutating two amino acids at positions 41 and 42
(from IA to MV) in the APP protein (Fig. 2B, 1). This should
exclude the readout for Aβ formation and retain the readout for
Aβ degradation. Second, a murine Ig κ-chain V-J2-C signal
peptide and hemagglutinin A epitope (HA) were added to the N-
terminus (Fig. 2B, 1). The added signal peptide helps to ensure
targeting of all fusion proteins to the membrane, thus reducing
the background nucleus translocation. An HA tag was added for
easy cell surface detection. Aβ40/42-specific ELISA confirmed
that Aβ42 production was completely abolished and the Aβ40
production was reduced by half in the mutant when both wild-
type amyloid precursors (APP695wt) and mutant APP695MV
were tested in HEK293T cells by transient transfection (data not
shown). These mutations also significantly reduced the
luciferase activities resulting from pNotch-AβMV cleavage to
one-seventh of that of the wild-type pNotch-Aβ (Fig. 2C),
further proving that the MV point mutations resulted in
reduction of APP cleavage by γ-secretase. A Renilla luciferase
reporter was cotransfected to control for transfection efficiency.
Thus, an increase in degradation of Aβ40 and Aβ42 is reflected
by an increase in the ratio of firefly to Renilla luciferase signal.
Fig. 2. Reporter assay for Aβ cleavage. (A) The scheme of the modified luciferase reporter assay for Aβ cleavage. (B) The vector systems for cotransfection luciferase
assay. 1 + 2: pNotch-AβMV + pHES-Luc, a modified reporter system for Aβ cleavage. 3: Renilla luciferase internal control vector. 4: pHUMU (vector) (pHUMU-
siNL_library). The structure of the opposing promoter siRNA gene expression cassette was described previously by Yu et al. [21]. (C) Significantly reduced
background for Aβ cleavage by γ-secretase through a mutation that removes γ-secretase cleavage sites. (D) Assay validation using the genes known to promote Aβ
cleavage. NEP (neprilysin), PSN (presenilin), and IDE (insulin-degrading enzyme) expression plasmids were cotransfected into HEK293T cells along with the
luciferase reporter system. The relative luciferase activities compared to control vector are represented.
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in this cell system resulted from the two dominant γ-secretase
activities, leading to the production of the toxic Aβ peptides.
A number of enzymes are known to reduce levels of the
Aβ40/42 peptide species, including neprilysin (NEP), presenilin
(PSN), insulin-degrading enzyme (IDE), angiotensin-converting
enzyme, and matrix metalloprotease-9 (MMP-9), which cleave
upstream of the dominant γ-secretase sites (Fig. 2B, 1) [16]. To
validate our assay, we cotransfected NEP, PSN, or IDE
expression plasmids with the new reporter system (Fig. 2B,
plasmids 1, 2, 3) into HEK293T cells. We observed an increase
in the firefly luciferase signal with expression of all three
enzymes, up to 200% over the endogenous protease levels (Fig.
2D). It is worth pointing out that without the introduced
mutations, the background reading is too high for detecting these
activities due to the endogenous γ-secretase activities (data not
shown). We also adapted this assay to a 96-well format for
screening siRNA and cDNA libraries as well as compound
libraries (C. Rogers et al., unpublished data).
Identification of NHRs involved in the APP cleavage upstream
of γ-secretase sites
We screened the pHUMU-NHR-siRNA library using the Aβ
degradation reporter assay in 96-well plates. HEK293T cells in
each well were cotransfected with pNotch-AβMV, pHES-Luc,
and SV40-Renilla plasmids (Fig. 2B, 1, 2, and 3) and pHUMU-
siNR-Lib (Fig. 1A or 2B, 4). Each transfection was in triplicate.
Luciferase activity was measured 2 days posttransfection. A
total of five 96-well plates with 4800 clones in 480 wells were
screened. Ten wells demonstrating >30% increase in the ratio of
firefly to Renilla luciferase signals for the siRNA library over
the control vector were considered as initial “hits.” Repeating
the test of the 10 pooled hits confirmed 6 of them with >30%
increase in luciferase signaling. These 6 pools were then
deconvoluted to identify the functional siRNA vectors by
testing individual siRNA vectors using the same assay. In the
end, a total of four siRNA vectors were shown to have
statistically significantly increased luciferase signal (Fig. 3A),
with some of the clones being redundant vectors found in
different positive pools.
The sequences of these final four siRNAvectors were used to
identify four potential candidate NHR targets (see Table 3):
NR4A2, NR113, ROR-γ (RAR-related orphan receptor-γ or
RORC or NR1F3), and NR6A1 by the BLASTN nr database
(NCBI). All these siRNAs contain 100% continuous homology
across >16 bp of siRNA sequences in the center with the
candidate targets (see Table 3). As an example, the transcript of
siRNA vector ID4_16 has a 17-nucleotide perfect match with
the RORC nucleotide positions 250–267 and an additional
match at position 247 of RORC (Fig. 3B). As is known, a
mismatch, or lower internal thermostability, at the 5′ end of the
antisense strand of siRNA not only is tolerated, but also can
potentially enhance the potency of RNAi [23,24]. Therefore,
RORC could be a potential target for the siRNAvector ID 4_16.
To confirm whether these candidate receptors were truly
responsible for the expected phenotypes, we repeated theexperiments using chemically synthesized siRNA designed
against unique regions of each of the four NHR sequences
outside the Zn_F_C4 region. Two siRNAs for each candidate
target (except only one siRNA for NR4A2) were used in the
study. Our data confirmed that the siRORC-1 mediated ROR-γ
silencing (Fig. 4A) and increased luciferase reporter activity by
nearly 250% (Fig. 3C). RORC-2 siRNA did not down-regulate
RORC (Fig. 4A) and did not cause elevated luciferase activity
(Fig. 3C). This strong correlation between the increase in
luciferase activity and the RORC silencing suggests that RORC
likely influences the degradation of the Aβ peptides upstream of
the γ-secretase sites. On the other hand, the siRNAs against the
other three potential candidates (Table 3) did not confirm that
the increase in reporter activities correlated with gene silencing,
suggesting that these three receptors are unlikely to be involved
in Aβ degradation (Fig. 3C). The effects observed by the siRNA
vectors from the library likely resulted from other undetermined
targets.
Retinoic acid is reported to be a natural agonist ligand for
RORC [14]. If RORC is involved in Aβ cleavage, retinoic acid
treatment should therefore down-regulate the cleavage, in
contrast to the RORC silencing. We treated the cells with
retinoic acid and assayed for luciferase reporter activity. Indeed,
we observed that this treatment lowered reporter activity (Fig.
3D). This suggests that retinoic acid causes a reduction in Aβ
cleavage via RORC at physiological concentration [25],
consistent with our RNAi experiments. However, we should
also realize that retinoic acid is a ligand for many other receptors
and not specific for RORC. Therefore, this particular experi-
ment cannot rule out that the retinoic acid effects resulted from a
mechanism other than RORC.
Confirmation of ROR-γ involvement in Aβ degradation
There are at least two mechanisms that determine the
ultimate output of the toxic Aβ peptides: Aβ formation by γ-
secretase cleavage and Aβ degradation by other activities
upstream of these two sites. To determine if siRNA-mediated
ROR-γ silencing actually resulted in degradation of the Aβ
peptides, we assessed Aβ42 production in ID11 cells with or
without siROR-γ treatment, using the Aβ42-specific ELISA.
ROR-γ siRNA was transfected into ID11 cells and the culture
media were assayed for Aβ42 by ELISA. To control for toxicity
induced by the expression of various siRNAs, a WST assay was
also carried out in parallel. No significant toxicity was found for
any of the siRNAs expressed (data not shown). Real-time RT-
PCR (TaqMan) revealed 80% knockdown of the ROR-γmRNA
mediated by the siRORC-1 (Fig. 4A). These transfected cells
also demonstrated consistent reduction of Aβ42 by nearly 20%
(Fig. 4B). siRORC-2, which did not knock down ROR-γ
expression, also did not decrease Aβ42 expression. These
results confirmed that the increase in cleavage occurring
upstream of the major γ-secretase sites over the basal level
can actually be translated into a reduction in the toxic Aβ
peptides. The 20% reduction at the peptide level is significant,
considering that the toxic peptides are generated mainly by γ-
secretase activities that account for the dominant cleavages of
Fig. 3. Identification of nuclear receptors that promote the Aβ cleavage. (A) pMUMU-siNR vectors that increased luciferase reporter activity. (B) Sequences of siRNA
vector 4_16 and its potential target RORC. The underlined sequences are the actual siRNA sequences isolated from the library; sequences in italic are the potential
target sequences; bold indicates matched sequences between siRNA and the targets. (C) Luciferase reporter activities caused by the chemically synthesized siRNAs
specifically against the selected nuclear hormone receptors. SCR-01 is a control siRNA (siCTL). (D) Retinoid acid treatment decreases the luciferase reporter activities.
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are relatively minor (compare Figs. 2C and 2D).
Discussion
We have described a new and simple method to design and
create RNAi libraries against any gene family that contains aconserved sequence motif. The RNAi libraries thus generated
can be delivered either in an opposing promoter siRNA
expression cassette, as described in this report, or in a short
hairpin RNA expression cassette [26] (Zhou, unpublished data).
Most protein families are usually classified according to the
characteristic functional domains consisting of conserved
motifs at the amino acid level, which are further reflected by
Table 3
siRNAs that were confirmed for reporter activity and their potential targets
siRNA ID Sequence Candidate target: accession No. (matches)
2_11 AAGTGCTGTGAGGGCTGCAAAGGACTTTT NR4A2: BC_066890 (18/21)
5_12 AAGTCCTGTGAGGGCTGCAAAGGTCTTTT NR6A1: NM_001489 (17/21)
4_16 AAGAGTTGTGAGGGGTGCAAGGGACTTTT RORC: NM_005060 (18/21)
5_7 AAGACTTGTGAGGGCTGCAAAGGACTTTT NR1I3: NM_005122 (17/21)
289J.-P. Yang et al. / Genomics 88 (2006) 282–292a certain degree of consensus sequences at the nucleic acid
level. These families include phosphatases, protein kinases,
metalloproteases, transferases, GTPases, ATPases, etc. There
are a few exceptional gene superfamilies, notably G-protein-
coupled receptors, that apparently lack such conserved
domains. However, there may still be certain conserved motifs
for some of their subfamilies. The existence of consensus
sequences makes it possible to design partially randomized
RNAi libraries targeting these predetermined families of
proteins. There is complete flexibility in the library design in
terms of the degree of randomization. A higher degree of
randomization covers more potential permutations of the gene
sequence but increases library complexity and thus the
downstream workload. We have demonstrated two important
approaches to reduce the complexity while maintaining
representation in member coverage in this report. First, a
protein family is divided into subgroups in which the degree of
consensus among the subgroup members is significantly higher
than that among the subgroups. The complexity of the library is
inversely correlated to the degree of subdivision of the proteinFig. 4. ROR-γ promotes Aβ production. (A) Silencing of ROR-γ by specific
siRNA measured by real-time RT-PCR. (B) ROR-γ silencing reduces the Aβ
production measured by Aβ ELISA.family and also to the total number of siRNA oligonucleotides
needed to be synthesized. One extreme is that each subgroup
will have only one member and thus no randomization is
needed. Hence, the lowest complexity is achieved and the
highest number of oligonucleotides will be synthesized.
Obviously a balance during the library design should be
considered according to the aims of the study as well as the
required downstream process. For example, if the downstream
assay is a simple positive selection such as cell survival [10,12]
or FACS sorting [27], a pooled library can be used effectively
and a more complex library would not be problematic. Second,
codon preference (e.g., in mammals) was utilized during the
reverse translation step to reduce complexity of codon usage
during reverse translation according to the weighted preference
in mammalian cells, which also significantly reduced the
complexity of the library. In the study presented here, however,
we have used the extreme case of using the codons that
appeared only in the actual genes.
The method described in this report provides a practical
solution. First, it simplifies oligonucleotide synthesis and
provides a single-step cloning approach, thereby speeding up
the process while reducing cost. Second, it allows for the
delivery of the RNAi libraries in a pooled fashion, such as the
one delivered by lentiviral vectors (Zhou et al., unpublished), as
well as in an arrayed format for cotransfection [3], making the
library sufficiently flexible for different combinatorial screen-
ings. Third, it provides a high degree of flexibility in the library
design so that the complexity of the library can readily be
manipulated according to the study goals. Finally, it also allows
for the possibility (via techniques such as inverse genomics)
[11,12,28] for the discovery of novel members of the gene
family of interest.
We first created a NHR siRNA library for a proof-of-
principal study because NHR is a small protein family and
contains a readily identified characteristic domain. Although
conventional preparation of an arrayed library can be achieved
for small groups of genes without particular difficulty, the
creation of the NHR library nevertheless validates the general
principle for larger gene family libraries. NHRs are considered
highly targetable either by agonists or by antagonists, since
there are many known natural or synthetic ligands for these
genes. It is also an important protein family in regulating gene
expression and other critical aspects of cellular physiology and
pathology [13,14]. In a separate screening using this NHR
siRNA library, we have used the G6P promoter–luciferase
reporter assay to identify receptors in the liver that are involved
in regulating gluconeogenesis. In that study, we identified LXRs
and RXRs, both already known to regulate G6Pase gene
expression [29,30], as well as a novel target [31].
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can tolerate certain mismatches, particularly at both ends. In
fact, it has been found that lower thermal stability at the 5′ end
of the antisense strand actually increases the siRNA potency
[23,24]. This information is important in guiding the BLAST
search using siRNA sequence against the genomic databases to
identify the potential candidate targets. On the other hand,
“off-target” effects remain an issue, particularly for the library
design based on degenerate sequences. We noticed the off-
target effect when only one target (RORC) was confirmed by
additional siRNA. Therefore, it is critical to design multiple
validation siRNAs, to confirm the candidate target for this type
of RNAi library strategy. An alternative approach to reduce the
false-negative rate is to design a library against more than one
consensus motif.
The hallmark of AD progression is the formation of
amyloid deposits, which are thought to cause neuronal cell
degradation [15]. Amyloid plaques are primarily made of the
toxic amyloid β peptides Aβ40 and Aβ42 which are
generated by cleavage by β- and γ-secretases. This amyloid
hypothesis is one of the most accepted AD etiology theories
at present. Our goal is to reduce the toxic peptides by
enhancing cleavage between the β- and the γ-secretase sites.
We identified RORC as a potential gene target whose
inactivation can increase cleavage of the toxic Aβ peptides.
The confirmation that the RORC inactivation indeed reduced
the overall toxic Aβ peptide levels suggests the relevance of
Aβ cleavage upstream of the major γ-secretase sites to the
reduction of the overall toxic peptide levels. Although the
level was modest, it was suggested that a slight reduction in
Aβ42 levels, especially if it lowers the ratio of the toxic
Aβ42 to Aβ40 and other cleavage products, could signifi-
cantly benefit patients. Therefore, this discovery of RORC as
a possible target for Aβ degradation could open a potential
novel avenue for AD therapeutics development.
Northern blot analysis has revealed that the 3.2-kb ROR-γ
transcript is expressed at the highest levels in skeletal muscle
and at lower levels in various other tissues [32]. In silico data
from the NCBI database reveals ROR-γ mRNA expression in
many brain regions, although there are no data on AD patients.
Many experiments can be performed to verify further whether
RORC is relevant to Aβ degradation in brain. An adequate cell-
based assay such as assays to check the downstream effects of
RORC on the activity of certain enzymes, e.g., MMP-9, IDE,
and neprilysin, or ultimately in vivo silencing of ROR-γ in an
AD animal model could provide the valuable validation
information. If RORC is proven to be a suitable drug target
for AD, new RORC-specific antagonists, particularly those that
can pass the blood–brain barrier, could be identified for
potential therapeutics and prevention of AD.Materials and methods
Cells
The HEK293 cell line was obtained from ATCC and cultured in Dulbecco’s
modified Eagle’s medium (Invitrogen, Carlsbad, CA, USA), supplemented with10% fetal bovine serum (Invitrogen), 2 mM L-glutamine (Fisher Scientific), 1×
nonessential amino acids (Irvine Scientific, Santa Ana, CA, USA), and 1%
sodium pyruvate (Invitrogen).
APP695sw stable cells overexpressing Swedish mutant amyloid precursor
protein were generated by stable cotransfection of APP695sw expression
plasmid and pcDNA3 vector (to provide a G418 selection marker) into
HEK293T cells followed by selection with G418. A single cell clone named
1D11 secreting high levels of Aβ42/40 detected by ELISA was chosen for the
experiment. The APPsw695 mutant allele was isolated from a familial AD
patient who was shown to generate high levels of the toxic Aβ fragments Aβ42
and Aβ40 [18–20].
Vector construction
Construction of the NHR RNAi library arrayed in 96 wells
The construction of pHUMU vector was previously described [3]. The
nine different oligos of 21-mers (Table 2) plus flanking sequences (see Fig.
1) were chemically synthesized (IDT) and were pooled according to their
weight within the family. The oligos were annealed with adaptor oligos to
form a partially double stranded and partially single-stranded structure,
which was subsequently ligated into the digested pHUMU fragment [3]. The
ligated vectors with a single-stranded region in the siRNA sequences were
transformed into bacteria. The bacteria were allowed to complete second-
strand synthesis by filling in the single-stranded region in vivo. The library-
vector-transformed bacteria were plated at a density at which the individual
colonies were separated from each other. The colonies were harvested as a
pooled library and stored at −80°C. To prepare for the arrayed library,
∼4800 colonies were picked and cultured separately in 1.8-ml 96-well plates
(Qiagen) overnight and until the end of log phase to ensure similar ODs.
Each of 10 well cultures was pooled and the plasmids were prepared from
them using Qiagen DNA prep kits, and the DNAs were arrayed into five
96-well plates. DNA concentrations were measured with the PicoGreen
Assay (Invitrogen) and normalized to 0.1 μg/μl, ready for screening
purposes.
Construction of pNotch-AβMV
pCxNC53NICD and pGV-B-HES-1 were obtained from Dr. Komano.
pNotch-AβMV was constructed by the following procedure. First, a murine
Igκ-chain V-J2-C signal peptide DNA fragment was generated by PCR
using the primer pair 5′-ATCTGGTACCTCCACCATGGAGACAGAC-3′
and 5′-ATCTGGTACCGAGATCTGGCCGGCTGG-3′. Second, this frag-
ment and the hemagglutinin A epitope from pDisplay (Invitrogen) were
added to the N-terminal of the Aβ peptide using a KpnI restriction site in
pCxNC53NICD. Furthermore, two point mutations were introduced into the
Aβ sequence to disrupt the major γ-secretase cleavage by site-directed
mutagenesis at positions 41 and 42 using primers 5′-ATGGTGG-
GCGGTGTTGTCatggtgACAGTGATCGTCATCACCT-3′ and 5′-AGGT-
GATGACGATCACTGTcaccatGACAACACCGCCCACCAT-3′ (lowercase
indicates the mutated sites) according to the protocol of the Quikchange
site-directed mutagenesis kit (Stratagene).
Other constructs
The SV40-Renilla luciferase expression vector was purchased from
Promega (Madison, WI, USA); NEP expression plasmid was kindly
provided by Dr. Shiotani. IDE and PSN expression plasmid was cloned
from a cDNA library (Clontech, Palo Alto, CA, USA) by PCR and inserted
into the expression plasmid pcDNA vector (Invitrogen); APP695wt (wild
type) expression plasmid was generated by PCR from APP770 expression
plasmid that was purchased from Origene. The primers used for PCR were
5′-TCTGTGGAAGAGGTGGTTCGAGTTCCTACAACAGCAGCCAG-
TACC-3′ and 5′-GGTACTGGCTGCTGTTGTAGGAACTCGAAC-
CACCTCTTCCACAGA-3′. APP695sw (Swedish mutant) and APP695MV
(γ-secretase mutant) were generated from APP695wt by a site-directed
mutagenesis kit (Stratagene). The primers for generated APP695sw were 5′-
GAGGAGATCTCTGAAGTGaatctgGATGCAGAATTCCGACAT-3′ and 5′-
ATGTCGGAATTCTGCATCcagattCACTTCAGAGATCTCCTC-3′. All the
constructs were confirmed by sequencing analysis.
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Cotransfection of four plasmids, pNotch-AβMV (50 ng/well), pHES-Luc,
SV40-Renilla (5 ng/well) (Fig. 2B, 1–3), and one of the various transgene
vectors (e.g., pNEP and pcDNA-PSN and IDE) (150 ng/well) into HEK293T
cells in 96-well plates was carried out as previously described [3]. Briefly, the
cells were seeded in 96-well plates (12,000 cells per well) on day 1 and
transfected on day 2 with these four plasmids using LT1 (0.5 μl/well) in a
total transfection volume of 25 μl in OptiMem medium (Invitrogen).
Luciferase activity was measured on day 4 using the Dual-Luciferase kit as
instructed by the manufacturer. pHUMU-siRNA library vector screening was
performed essentially the same way as for the above four-plasmid vector
cotransfection (Fig. 2B, 1–4), except that the transgene plasmid vector was
replaced with the siRNA library.
Transfection of HEK293T with siRNA
The siRNAs were purchased from Dharmacon. The siRNA transfection
was previously described [21]. The siRNA sequences were (1) NR1I3
NM_005122, #1_sense, 5′-CCUCUUCGCUACACAAUUGUU, antisense,
5′-P-CAAUUGUGUAGCGAAGAGGUU; (2) NR1I3 NM_005122,
#2_sense, 5′-GAACAGUUUGUGCAGUUUAUU, antisense, 5′-pUAA-
ACUGCACAAACUGUUCUU; (3) RORC, NM_005060, #1_sense,
5′-UCACCGAGGCCAUUCAGUAUU, antisense, 5′-pUACUGAAUGGC-
CUCGGUGAUU; (4) RORC, NM_005060, #2_sense, 5′-AGAACAGCUG-
CAGUACAAUU, antisense, 5′-pUACUGAAUGGCCUCGGUGAUU; (5)
NR6A1, NM_001489, #1_sense, 5′-CAACGAACCUGUCUCAUUUUU,
antisense, 5′-pAAAUGAGACAGGUUCGUUGUU; (6) NR6A1,
NM_001489, #2_sense, 5′-GAAGAACUACACAGAUUUAUU, antisense,
5′-pUAAAUCUGUGUAGUUCUUCUU; (7) NR4A2, BC_066890, sense, 5′-
GAGAGUGGAAGAACUGCAAUU, antisense, 5′-pUUGCAGUUCUUCCACUCUCUU.
Gene expression analysis
TaqMan real-time PCR was performed as previously described [21]. Briefly,
total RNA was isolated from different cell lines using the RNeasy kit (Qiagen)
according to the manufacturer’s protocol. Real-time RT-PCR (TaqMan) was
carried out using the Prism 7700 sequence detector (Applied Biosystems) and
dual-labeled fluorescent probe and PCR primers targeting the human ROR-γ
coding region (probe, 5′-6FAM/AGTTCGCCAAGAGGCTCTCAGGCTTT/
3BHQ; forward primer, 5′-CTCACCGAGGCCATTCAGTAC-3′; reverse
primer, 5′-CTGGTCATTCTGGCAGAGCTC-3′). Each RNA sample was
analyzed in triplicate in two independent assays of RT-PCR with reaction
consisting of the following steps: hold 48°C × 30 min; 95°C × 15 s and
60°C × 1 min for 40 cycles. The relative PLK mRNA levels were normalized to
the level of the 18S rRNA internal control (Applied Biosystems).
ELISAs for Aβ40 and toxic Aβ42 peptides
ELISAs for toxic Aβ42 and Aβ40 peptides were carried out using
standard ELISA procedures. Briefly, culture media were collected and cell
debris was removed by centrifugation. Aβ40 and Aβ42 levels were
quantified by sandwich ELISA according to the manufacturer’s instructions
(BioSource International, Camarillo, CA, USA). All the measurements were
performed in triplicate.
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